Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Lex is sceptical about Facebook’s glasses launched with Ray-Ban on Thursday....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Among other assignments, he advised Time Warner on its $80bn merger with AT&T, and represented Wyeth during its $68bn sale to Pfizer....
...Automation an automatic choiceJapan Inc has found a new purpose for automation: business continuity in the uncertain era of Covid-19....
...When three groups announced in quick succession this month that the vaccines they had developed against Covid-19 had proved highly effective in clinical trials, the news offered not only a blazing ray of...
...ICU is in the process of integrating its $900m acquisition of Hospira Infusion Systems last year from Pfizer, a business that Smiths had also been interested in purchasing....
...Pfizer on Monday added a further $10bn share repurchase authorisation to the $6.4bn that remained under its previous programme....
...Analysts suggest the fall in Bristol-Myers’ value has turned it into a takeover target, most likely for Pfizer or Novartis ....
...Ian Read, chief executive of New York-based Pfizer, said last week the US tax code left his team “with one hand tied behind our back” in competition with foreign rivals....
...Ray Hill, former head of the British Pharmacological Society, agrees. “There is an issue in how to keep those skills alive, so when people are ready to reinvest there are people here to hire.”...
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...The gigantic offer for AstraZeneca by Pfizer is, or should be, a bellwether event. It has nothing obvious to recommend it, except that the US pharmaceuticals group should save on its tax liabilities....
...The scene: a twenty-something wakes to see standing over him a huge black-clad figure wearing Ray-Bans and talking with an Austrian accent. Wake up, John Connor. Who are you....
...Drugs are commonly posted mislabelled as other products or wrapped in tin foil to conceal them from X-ray scans at centres such as Coventry’s postal sorting office, another venue for Operation Pangea this...
...Twilight, Romney v Obama....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...3D disc – a copy of Dreamworks’ Monsters v Aliens....
...For example, Argonaut Capital Management remains downbeat in its medium-to-long outlook for the US, but sees “rays of light” appearing in the short term....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...He remembers uncapping a black marker to write: R squared over A is V+, in what he calls a type of epiphany....
...“Companies have recognised there is no comparative advantage in safety,” says Ray Woosley, Critical Path president....
International Edition